| Literature DB >> 27379855 |
Abstract
Chronic venous disease (CVD) affects at least 15-25 % of the general population incurring not only high morbidity but also considerable economical burden. The mainstay of modern treatment of CVD are endovenous therapeutic procedures and compression therapy. As far as the pathogenesis of CVD is being gradually unraveled the interest in drugs able to impact the process is growing. Here we have presented an overview of a majority of oral preparations used so far to treat CVD including venous leg ulcers. After several decades of clinical use a few flavonoid preparations, in the first place micronized purified flavonoid fraction, collected enough evidence to recommend them as a short-term adjunct treatment of CVD. However, other compounds are also promising in this regards. Yet, we need more larger and longer-term clinical trials to more precisely define effects, cost-effectiveness and, above all, capacity for prophylactic application of the drugs. Learning more about basis of CVD will help design new drugs directed at specific aspects of the disease process.Entities:
Keywords: Benzopyrones; Calcium dobesilate; Chronic venous disease; Drugs; Flavonoids; Oral treatment; Varicose veins
Mesh:
Substances:
Year: 2016 PMID: 27379855 DOI: 10.1007/s10354-016-0480-z
Source DB: PubMed Journal: Wien Med Wochenschr ISSN: 0043-5341